294 related articles for article (PubMed ID: 34961486)
1. Perspectives and potential approaches for targeting neuropilin 1 in SARS-CoV-2 infection.
Chapoval SP; Keegan AD
Mol Med; 2021 Dec; 27(1):162. PubMed ID: 34961486
[TBL] [Abstract][Full Text] [Related]
2. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.
Cantuti-Castelvetri L; Ojha R; Pedro LD; Djannatian M; Franz J; Kuivanen S; van der Meer F; Kallio K; Kaya T; Anastasina M; Smura T; Levanov L; Szirovicza L; Tobi A; Kallio-Kokko H; Österlund P; Joensuu M; Meunier FA; Butcher SJ; Winkler MS; Mollenhauer B; Helenius A; Gokce O; Teesalu T; Hepojoki J; Vapalahti O; Stadelmann C; Balistreri G; Simons M
Science; 2020 Nov; 370(6518):856-860. PubMed ID: 33082293
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment.
Wu CT; Lidsky PV; Xiao Y; Lee IT; Cheng R; Nakayama T; Jiang S; Demeter J; Bevacqua RJ; Chang CA; Whitener RL; Stalder AK; Zhu B; Chen H; Goltsev Y; Tzankov A; Nayak JV; Nolan GP; Matter MS; Andino R; Jackson PK
Cell Metab; 2021 Aug; 33(8):1565-1576.e5. PubMed ID: 34081912
[TBL] [Abstract][Full Text] [Related]
4. Biophysical investigation of interactions between SARS-CoV-2 spike protein and neuropilin-1.
Hou D; Cao W; Kim S; Cui X; Ziarnik M; Im W; Zhang XF
Protein Sci; 2023 Oct; 32(10):e4773. PubMed ID: 37656811
[TBL] [Abstract][Full Text] [Related]
5. Neuropilin-1 is a host factor for SARS-CoV-2 infection.
Daly JL; Simonetti B; Klein K; Chen KE; Williamson MK; Antón-Plágaro C; Shoemark DK; Simón-Gracia L; Bauer M; Hollandi R; Greber UF; Horvath P; Sessions RB; Helenius A; Hiscox JA; Teesalu T; Matthews DA; Davidson AD; Collins BM; Cullen PJ; Yamauchi Y
Science; 2020 Nov; 370(6518):861-865. PubMed ID: 33082294
[TBL] [Abstract][Full Text] [Related]
6. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
7. The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies.
Zalpoor H; Akbari A; Samei A; Forghaniesfidvajani R; Kamali M; Afzalnia A; Manshouri S; Heidari F; Pornour M; Khoshmirsafa M; Aazami H; Seif F
Cell Mol Biol Lett; 2022 Feb; 27(1):10. PubMed ID: 35109786
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
9. Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?
Gadanec LK; McSweeney KR; Qaradakhi T; Ali B; Zulli A; Apostolopoulos V
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498183
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 pseudovirus infectivity and expression of viral entry-related factors ACE2, TMPRSS2, Kim-1, and NRP-1 in human cells from the respiratory, urinary, digestive, reproductive, and immune systems.
Zhang F; Li W; Feng J; Ramos da Silva S; Ju E; Zhang H; Chang Y; Moore PS; Guo H; Gao SJ
J Med Virol; 2021 Dec; 93(12):6671-6685. PubMed ID: 34324210
[TBL] [Abstract][Full Text] [Related]
11. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
[TBL] [Abstract][Full Text] [Related]
12. Discovery of natural products to block SARS-CoV-2 S-protein interaction with Neuropilin-1 receptor: A molecular dynamics simulation approach.
Alshawaf E; Hammad MM; Marafie SK; Ali H; Al-Mulla F; Abubaker J; Mohammad A
Microb Pathog; 2022 Sep; 170():105701. PubMed ID: 35963279
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
14. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
15. Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1.
Hashizume M; Takashima A; Ono C; Okamoto T; Iwasaki M
Antiviral Res; 2023 Jan; 209():105481. PubMed ID: 36481388
[TBL] [Abstract][Full Text] [Related]
16. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
Choudhury A; Mukherjee S
J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
[TBL] [Abstract][Full Text] [Related]
17. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
[TBL] [Abstract][Full Text] [Related]
18. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
19. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
20. Host Cell and SARS-CoV-2-Associated Molecular Structures and Factors as Potential Therapeutic Targets.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Roshan R; Azam F; Mehta J; Handu S; Prasad R; Jain N; Pandey AK; Dhamija P
Cells; 2021 Sep; 10(9):. PubMed ID: 34572076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
